FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2061911339> ?p ?o ?g. }

• W2061911339 endingPage "23" @default.
• W2061911339 startingPage "15" @default.
• W2061911339 abstract "BackgroundDespite its proven efficacy, infliximab is often considered to be an expensive treatment for patients with psoriatic arthritis.ObjectivesTo estimate the cost-effectiveness of infliximab among patients with active and progressive psoriatic arthritis.MethodsA decision analytic model was constructed to simulate disease progression in hypothetical cohorts of patients with psoriatic arthritis receiving infliximab maintenance treatment. The primary response measure was change in Health Assessment Questionnaire score from a baseline estimated from mixed treatment models drawn from published clinical trials. Palliative care, comprising nonbiologic disease-modifying antirheumatic drugs, was used as a comparator. The primary outcome was quality-adjusted life years. The dose of infliximab was estimated for a range of 60 to 80 kg per patient body weight. The costs and outcomes were discounted at 3.5% for a period of 40 years. Uncertainty around the results was explored with probabilistic sensitivity analysis.ResultsThe mixed treatment comparison showed a significant reduction in Health Assessment Questionnaire score across all patients. The tumor necrosis factor α inhibitors were significantly superior to palliative care but comparable with one another. The incremental cost-effectiveness ratios for etanercept, adalimumab, and infliximab relative to palliative care were £17,327; £19,246; and £16,942 to £23,022, respectively, across all patients with psoriatic arthritis and £16,613; £18,170; and £15,788 to £21,736, respectively, in the subgroup with significant psoriasis.ConclusionInfliximab represents a cost-effective treatment option well within the National Institute for Health and Clinical Excellence threshold relative to palliative care. In light of equivalent outcomes with other tumor necrosis factor α inhibitors, its position in the treatment pathway is likely to be governed by treatment costs." @default.
• W2061911339 created "2016-06-24" @default.
• W2061911339 creator A5002789537 @default.
• W2061911339 creator A5019479654 @default.
• W2061911339 creator A5024780684 @default.
• W2061911339 creator A5030471784 @default.
• W2061911339 creator A5045480153 @default.
• W2061911339 creator A5082515232 @default.
• W2061911339 creator A5088628821 @default.
• W2061911339 date "2011-01-01" @default.
• W2061911339 modified "2023-10-01" @default.
• W2061911339 title "Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis" @default.
• W2061911339 cites W1965742808 @default.
• W2061911339 cites W2089689228 @default.
• W2061911339 cites W2094124191 @default.
• W2061911339 cites W2099706116 @default.
• W2061911339 cites W2101695974 @default.
• W2061911339 cites W2109268320 @default.
• W2061911339 cites W2121025314 @default.
• W2061911339 cites W2129841863 @default.
• W2061911339 cites W2133694748 @default.
• W2061911339 cites W2133696182 @default.
• W2061911339 cites W2138763209 @default.
• W2061911339 cites W2144702115 @default.
• W2061911339 cites W2145778588 @default.
• W2061911339 cites W2149168537 @default.
• W2061911339 cites W2156796142 @default.
• W2061911339 cites W2163728790 @default.
• W2061911339 cites W2168698481 @default.
• W2061911339 doi "https://doi.org/10.1016/j.jval.2010.10.016" @default.
• W2061911339 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21211482" @default.
• W2061911339 hasPublicationYear "2011" @default.
• W2061911339 type Work @default.
• W2061911339 sameAs 2061911339 @default.
• W2061911339 citedByCount "12" @default.
• W2061911339 countsByYear W20619113392013 @default.
• W2061911339 countsByYear W20619113392014 @default.
• W2061911339 countsByYear W20619113392015 @default.
• W2061911339 countsByYear W20619113392017 @default.
• W2061911339 countsByYear W20619113392018 @default.
• W2061911339 countsByYear W20619113392019 @default.
• W2061911339 countsByYear W20619113392020 @default.
• W2061911339 countsByYear W20619113392023 @default.
• W2061911339 crossrefType "journal-article" @default.
• W2061911339 hasAuthorship W2061911339A5002789537 @default.
• W2061911339 hasAuthorship W2061911339A5019479654 @default.
• W2061911339 hasAuthorship W2061911339A5024780684 @default.
• W2061911339 hasAuthorship W2061911339A5030471784 @default.
• W2061911339 hasAuthorship W2061911339A5045480153 @default.
• W2061911339 hasAuthorship W2061911339A5082515232 @default.
• W2061911339 hasAuthorship W2061911339A5088628821 @default.
• W2061911339 hasBestOaLocation W20619113391 @default.
• W2061911339 hasConcept C112930515 @default.
• W2061911339 hasConcept C126322002 @default.
• W2061911339 hasConcept C159110408 @default.
• W2061911339 hasConcept C16005928 @default.
• W2061911339 hasConcept C17991360 @default.
• W2061911339 hasConcept C1862650 @default.
• W2061911339 hasConcept C2776260265 @default.
• W2061911339 hasConcept C2777077863 @default.
• W2061911339 hasConcept C2777138892 @default.
• W2061911339 hasConcept C2777226972 @default.
• W2061911339 hasConcept C2779134260 @default.
• W2061911339 hasConcept C2779951463 @default.
• W2061911339 hasConcept C2780132546 @default.
• W2061911339 hasConcept C2780564577 @default.
• W2061911339 hasConcept C2994186709 @default.
• W2061911339 hasConcept C3019080777 @default.
• W2061911339 hasConcept C64332521 @default.
• W2061911339 hasConcept C71924100 @default.
• W2061911339 hasConceptScore W2061911339C112930515 @default.
• W2061911339 hasConceptScore W2061911339C126322002 @default.
• W2061911339 hasConceptScore W2061911339C159110408 @default.
• W2061911339 hasConceptScore W2061911339C16005928 @default.
• W2061911339 hasConceptScore W2061911339C17991360 @default.
• W2061911339 hasConceptScore W2061911339C1862650 @default.
• W2061911339 hasConceptScore W2061911339C2776260265 @default.
• W2061911339 hasConceptScore W2061911339C2777077863 @default.
• W2061911339 hasConceptScore W2061911339C2777138892 @default.
• W2061911339 hasConceptScore W2061911339C2777226972 @default.
• W2061911339 hasConceptScore W2061911339C2779134260 @default.
• W2061911339 hasConceptScore W2061911339C2779951463 @default.
• W2061911339 hasConceptScore W2061911339C2780132546 @default.
• W2061911339 hasConceptScore W2061911339C2780564577 @default.
• W2061911339 hasConceptScore W2061911339C2994186709 @default.
• W2061911339 hasConceptScore W2061911339C3019080777 @default.
• W2061911339 hasConceptScore W2061911339C64332521 @default.
• W2061911339 hasConceptScore W2061911339C71924100 @default.
• W2061911339 hasIssue "1" @default.
• W2061911339 hasLocation W20619113391 @default.
• W2061911339 hasLocation W20619113392 @default.
• W2061911339 hasOpenAccess W2061911339 @default.
• W2061911339 hasPrimaryLocation W20619113391 @default.
• W2061911339 hasRelatedWork W1533295161 @default.
• W2061911339 hasRelatedWork W1970925217 @default.
• W2061911339 hasRelatedWork W1980751609 @default.
• W2061911339 hasRelatedWork W2062801585 @default.
• W2061911339 hasRelatedWork W2084542616 @default.

• next